Assessing the Safety and Tolerability of ABBV-951 (Foscarbidopa/Foslevodopa) in Advanced Parkinson’s Disease Patients During a 52-Week Phase 3 Study: Study Design and Updated Patient Baseline Characteristics
Objective: To evaluate the local and systemic safety and tolerability of ABBV-951 (foscarbidopa/foslevodopa) delivered 24 h/day as a continuous subcutaneous infusion (CSCI) for up to…Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study
Objective: Evaluate the efficacy of apomorphine (APO) infusion in reducing OFF time during the hours of pump use in PD patients with motor fluctuations inadequately…Transcutaneous magnetic spinal cord stimulation for freezing of gait in Parkinson’s disease (PD)
Objective: To study the safety and efficacy of transcutaneous magnetic spinal cord stimulation (SCS) on freezing of gait (FoG) and other motor symptoms in a…Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics
Objective: Describe the study design of Part 2 of the MOVES-PD trial (NCT02906020), and report patient characteristics. Background: Mutations in the glucocerebrosidase (GBA) gene are…Daily Time-Course of Efficacy of Continuous Subcutaneous Infusion of Foslevodopa/foscarbidopa in Advanced Parkinson’s Disease Patients from a Phase 1b Study
Objective: Characterize and compare the time-course of Parkinson’s disease (PD) symptoms following 24h/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa and oral levodopa/carbidopa (LD/CD). Background: As…Ambulosono: A Novel Sensor-based System for Quantitative Evaluation Freezing of Gait in Parkinson’s disease
Objective: We prospectively evaluated the manifestations of On-Drug freezing of gait (FOG) of Parkinson’s disease (PD) in China using a novel sensor-based system. Background: FOG…Poly-ADP-ribose polymerase 1 modulates mitochondrial fission via LRRK2 in a rotenone-induced Parkinson’s disease model
Objective: To clarity the effects and mechanism of poly-ADP-ribose polymerase 1(PARP1) in regulating mitochondrial fusion/fission in a rotenone-induced Parkinson's disease (PD) model. Background: Accumulating evidences…Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) as first-line adjunctive therapy in levodopa/DOPA decarboxylase inhibitors-treated Parkinson’s disease (PD) patients…Effects of onabotulinum toxin A on balance and gait in Parkinson’s disease with foot dystonia: A case series study
Objective: To investigate the effectiveness of botulinum toxin (BoNT) in reducing the severity of dystonia and improving gait and balance in Parkinson’s disease (PD) patients…Beta-adrenoreceptor medications and risk of Parkinson’s disease
Objective: To review and analyze the associations between β-adrenoreceptor medications and risk of Parkinson's disease. Background: Distinctive Lewy body mainly composed of α-synuclein is an…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 149
- Next Page »